Clinical Reviews in Allergy & Immunology

, Volume 45, Issue 2, pp 202–210 | Cite as

Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweet’s Syndrome: a Comprehensive Review and Disease Classification Criteria

  • Angelo V. Marzano
  • Rim S. Ishak
  • Simone Saibeni
  • Carlo Crosti
  • Pier Luigi Meroni
  • Massimo Cugno
Article

Abstract

Pyoderma gangrenosum (PG) and Sweet’s syndrome (SS) are skin diseases usually presenting with recurrent ulcers and erythematous plaques, respectively. The accumulation of neutrophils in the skin, characteristic of these conditions, led to coin the term of neutrophilic dermatoses to define them. Recently, neutrophilic dermatoses have been included in the group of autoinflammatory diseases, which classically comprises genetically determined forms due to mutations of genes regulating the innate immune response. Both PG and SS are frequently associated with inflammatory bowel diseases (IBDs); however, IBD patients develop PG in 1–3 % of cases, whereas SS is rarer. Clinically, PG presents with deep erythematous-to-violaceous painful ulcers with well-defined borders; bullous, pustular, and vegetative variants can also occur. SS is characterized by the abrupt onset of fever, peripheral neutrophilia, tender erythematous skin lesions, and a diffuse neutrophilic dermal infiltrate. It is also known as acute febrile neutrophilic dermatosis. Treatment of PG involves a combination of wound care, topical medications, antibiotics for secondary infections, and treatment of the underlying IBD. Topical therapies include corticosteroids and the calcineurin inhibitor tacrolimus. The most frequently used systemic medications are corticosteroids and cyclosporine, in monotherapy or in combination. Dapsone, azathioprine, cyclophosphamide, methotrexate, intravenous immunoglobulins, mycophenolate mofetil, and plasmapheresis are considered second-line agents. Hyperbaric oxygen, as supportive therapy, can be added. Anti-TNF-α agents such as etanercept, infliximab, and adalimumab are used in refractory cases. SS is usually responsive to oral corticosteroids, and the above-mentioned immunosuppressants should be considered in resistant or highly relapsing cases.

Keywords

Inflammatory bowel diseases Pyoderma gangrenosum Sweet’s syndrome Autoinflammatory diseases 

References

  1. 1.
    Cohen PR (2009) Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 10:301–312PubMedCrossRefGoogle Scholar
  2. 2.
    Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 13:191–211PubMedCrossRefGoogle Scholar
  3. 3.
    Marzano AV, Trevisan V, Lazzari R, Crosti C (2011) Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification. J Dermatol Treat 22:254–260CrossRefGoogle Scholar
  4. 4.
    Nesterovitch AB, Gyorfy Z, Hoffman MD, Moore EC, Elbuluk N, Tryniszewska B, Rauch TA, Simon M, Kang S, Fisher GJ, Mikecz K, Tharp MD, Glant TT (2011) Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol 178:1434–1441PubMedCrossRefGoogle Scholar
  5. 5.
    Aksentijevich I, Kastner DL (2011) Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 7:469–78PubMedCrossRefGoogle Scholar
  6. 6.
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ, Kastner DL (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144PubMedCrossRefGoogle Scholar
  7. 7.
    Kastner DL, Aksentijevich I, Goldbach-Mansky R (2010) Autoinflammatory disease reloaded: a clinical perspective. Cell 140:784–90PubMedCrossRefGoogle Scholar
  8. 8.
    Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L, Ghirardello A, Iaccarino L, Punzi L (2012) Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 12:22–30PubMedCrossRefGoogle Scholar
  9. 9.
    Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961–9PubMedCrossRefGoogle Scholar
  10. 10.
    Dinarello CA (2011) A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 41:1203–1217PubMedCrossRefGoogle Scholar
  11. 11.
    Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361:2066–2078PubMedCrossRefGoogle Scholar
  12. 12.
    Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819–4831PubMedGoogle Scholar
  13. 13.
    Larsen S, Bendtzen K, Nielsen OH (2010) Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 42:97–114PubMedCrossRefGoogle Scholar
  14. 14.
    Wollina U (2002) Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 3:149–158PubMedCrossRefGoogle Scholar
  15. 15.
    Powell FC, Su WP, Perry HO (1996) Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 34:395–409, quiz 410–392PubMedCrossRefGoogle Scholar
  16. 16.
    Callen JP (1996) Pyoderma gangrenosum. Lancet 351:581–585CrossRefGoogle Scholar
  17. 17.
    Marzano AV, Ishak RS, Lazzari R, Polloni I, Vettoretti S, Crosti C (2012) Vulvar pyoderma gangrenosum with renal involvement. Eur J Dermatol 22:537–539PubMedGoogle Scholar
  18. 18.
    Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G (2009) Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 23:1008–1017PubMedCrossRefGoogle Scholar
  19. 19.
    Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, Crosti C (2010) Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 162:100–107PubMedCrossRefGoogle Scholar
  20. 20.
    O'Loughlin S, Perry HO (1978) A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 114:1061–1064PubMedCrossRefGoogle Scholar
  21. 21.
    Su WP, Davis MD, Weenig RH, Powell FC, Perry HO (2004) Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 43:790–800PubMedCrossRefGoogle Scholar
  22. 22.
    Conrad C, Trueb RM (2005) Pyoderma gangrenosum. J Dtsch Dermatol Ges 3:334–342PubMedCrossRefGoogle Scholar
  23. 23.
    Perry HO, Winkelmann RK (1972) Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 106:901–905PubMedCrossRefGoogle Scholar
  24. 24.
    Marzano AV, Trevisan V, Galloni C, Alessi E (2008) Fatal bullous pyoderma gangrenosum in a patient with Klinefelter’s syndrome. Acta Derm Venereol 88:158–159PubMedCrossRefGoogle Scholar
  25. 25.
    Wilson-Jones E, Winkelmann RK (1988) Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 18:511–521PubMedCrossRefGoogle Scholar
  26. 26.
    Marzano AV, Tourlaki A, Alessi E, Caputo R (2008) Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol 33:156–159PubMedCrossRefGoogle Scholar
  27. 27.
    Lyon CC, Smith AJ, Beck MH, Wong GA, Griffiths CE (2000) Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 42:992–1002PubMedCrossRefGoogle Scholar
  28. 28.
    Tjandra JJ, Hughes LE (1994) Parastomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum 37:938–942PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen PR, Kurzrock R (2003) Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol 42:761–778PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen PR, Almeida L, Kurzrock R (1989) Acute febrile neutrophilic dermatosis. Am Fam Physician 39:199–204PubMedGoogle Scholar
  31. 31.
    Carpentier O, Piette F, Delaporte E (2002) Sweet’s syndrome after BCG vaccination. Acta Derm Venereol 82:221PubMedCrossRefGoogle Scholar
  32. 32.
    Arbetter KR, Hubbard KW, Markovic SN, Gibson LE, Phyliky RL (1999) Case of granulocyte colony-stimulating factor-induced Sweet’s syndrome. Am J Hematol 61:126–129PubMedCrossRefGoogle Scholar
  33. 33.
    Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, Mizoguchi M (2004) Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 140:570–574PubMedCrossRefGoogle Scholar
  34. 34.
    Kumar G, Bernstein JM, Waibel JS, Baumann MA (2004) Sweet’s syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol 76:283–285PubMedCrossRefGoogle Scholar
  35. 35.
    Dereure O, Hillaire-Buys D, Guilhou JJ (2004) Neutrophil-dependent cutaneous side-effects of leucocyte colony-stimulating factors: manifestations of a neutrophil recovery syndrome? Br J Dermatol 150:1228–1230PubMedCrossRefGoogle Scholar
  36. 36.
    Cohen PR (2007) Sweet’s syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2:34PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen PR, Kurzrock R (2000) Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 18:265–282PubMedCrossRefGoogle Scholar
  38. 38.
    Neoh CY, Tan AW, Ng SK (2007) Sweet’s syndrome: a spectrum of unusual clinical presentations and associations. Br J Dermatol 156:480–485PubMedCrossRefGoogle Scholar
  39. 39.
    Bielsa S, Baradad M, Marti RM, Casanova JM (2005) Sweet’s syndrome with bullous lesions. Actas Dermosifiliogr 96:315–316PubMedCrossRefGoogle Scholar
  40. 40.
    Voelter-Mahlknecht S, Bauer J, Metzler G, Fierlbeck G, Rassner G (2005) Bullous variant of Sweet’s syndrome. Int J Dermatol 44:946–947PubMedCrossRefGoogle Scholar
  41. 41.
    Sommer S, Wilkinson SM, Merchant WJ, Goulden V (2000) Sweet’s syndrome presenting as palmoplantar pustulosis. J Am Acad Dermatol 42:332–334Google Scholar
  42. 42.
    Cohen PR (2005) Subcutaneous Sweet’s syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol 52:927–928PubMedCrossRefGoogle Scholar
  43. 43.
    Sweet RD (1964) An acute febrile neutrophilic dermatosis. Br J Dermatol 76:349–356PubMedCrossRefGoogle Scholar
  44. 44.
    Cooper PH, Frierson HF, Greer KE (1983) Subcutaneous neutrophilic infiltrates in acute febrile neutrophilic dermatosis. Arch Dermatol 119:610–611PubMedCrossRefGoogle Scholar
  45. 45.
    Cullity J, Maguire B, Gebauer K (1991) Sweet’s panniculitis. Australas J Dermatol 32:61–64PubMedCrossRefGoogle Scholar
  46. 46.
    Suzuki Y, Kuroda K, Kojima T, Fujita M, Iseki T, Shinkai H (1995) Unusual cutaneous manifestations of myelodysplastic syndrome. Br J Dermatol 133:483–486PubMedCrossRefGoogle Scholar
  47. 47.
    Cohen PR, Kurzrock R (1993) Sweet’s syndrome and cancer. Clin Dermatol 11:149–157PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen PR, Kurzrock R (1987) Sweet’s syndrome and malignancy. Am J Med 82:1220–1226PubMedCrossRefGoogle Scholar
  49. 49.
    Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P, DCCD study group (2006) Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 101:1274–1282PubMedCrossRefGoogle Scholar
  50. 50.
    Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106:110–119PubMedCrossRefGoogle Scholar
  51. 51.
    Williams H, Walker D, Orchard TR (2008) Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 10:597–605PubMedCrossRefGoogle Scholar
  52. 52.
    Requena L, Yus ES (2008) Erythema nodosum. Dermatol Clin 26:425–438PubMedCrossRefGoogle Scholar
  53. 53.
    Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A (2005) Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 11:7227–7236PubMedGoogle Scholar
  54. 54.
    Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116–1122PubMedCrossRefGoogle Scholar
  55. 55.
    Trost LB, McDonnell JK (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81:580–585PubMedCrossRefGoogle Scholar
  56. 56.
    Thornton JR, Teague RH, Low-Beer TS, Read AE (1980) Pyoderma gangrenosum and ulcerative colitis. Gut 21:247–248PubMedCrossRefGoogle Scholar
  57. 57.
    Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK (1991) Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78:676–678PubMedCrossRefGoogle Scholar
  58. 58.
    Menachem Y, Gotsman I (2004) Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 6:88–90PubMedGoogle Scholar
  59. 59.
    Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF (2001) Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg 18:51–55PubMedCrossRefGoogle Scholar
  60. 60.
    Mir-Madjlessi SH, Taylor JS, Farmer RG (1985) Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 80:615–620PubMedGoogle Scholar
  61. 61.
    Marzano AV, Trevisan V, Lazzari R, Crosti C (2010) Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatol Treat 21:140–143CrossRefGoogle Scholar
  62. 62.
    Timani S, Mutasim DF (2008) Skin manifestations of inflammatory bowel disease. Clin Dermatol 26:265–273PubMedCrossRefGoogle Scholar
  63. 63.
    Huang BL, Chandra S, Shih DQ (2012) Skin manifestations of inflammatory bowel disease. Front Physiol 3:13PubMedGoogle Scholar
  64. 64.
    Wasserteil V, Bruce S, Sessoms SL, Guntupalli KK (1992) Pyoderma gangrenosum treated with hyperbaric oxygen therapy. Int J Dermatol 31:594–596PubMedCrossRefGoogle Scholar
  65. 65.
    Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505–509PubMedCrossRefGoogle Scholar
  66. 66.
    Alkhouri N, Hupertz V, Mahajan L (2009) Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn’s disease. Inflamm Bowel Dis 15:803–806PubMedCrossRefGoogle Scholar
  67. 67.
    Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, Hoetzenecker W, Biedermann T (2011) Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 147:1203–1205PubMedCrossRefGoogle Scholar
  68. 68.
    Vij A, Modi GM, Suwattee P, Cockerell CJ, Hsu S (2010) Chronic, recurrent neutrophilic dermatosis: a case report. Dermatol Online J 16:1PubMedGoogle Scholar
  69. 69.
    Kemmett D, Hunter JA (1990) Sweet’s syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol 23:503–507PubMedCrossRefGoogle Scholar
  70. 70.
    Souissi A, Benmously R, Fenniche S, Zarrouk M, Marrek H, Debbiche A, Ayed MB, Mokhtar I (2007) Sweet’s syndrome: a propos of 8 cases. Tunis Med 85:49–53PubMedGoogle Scholar
  71. 71.
    Kemmett D, Gawkrodger DJ, Wilson G, Hunter JA (1988) Sweet’s syndrome in Crohn’s disease. BMJ 297:1513–1514PubMedCrossRefGoogle Scholar
  72. 72.
    Paoluzi OA, Crispino P, Amantea A, Pica R, Iacopini F, Consolazio A, Di Palma V, Rivera M, Paoluzi P (2004) Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet’s syndrome. Case report and review of literature. Dig Liver Dis 36:361–366PubMedCrossRefGoogle Scholar
  73. 73.
    Burrows NP (1995) Sweet’s syndrome in association with Crohn’s disease. Clin Exp Dermatol 20:279–280PubMedCrossRefGoogle Scholar
  74. 74.
    Ytting H, Vind I, Bang D, Munkholm P (2005) Sweet’s syndrome—an extraintestinal manifestation in inflammatory bowel disease. Digestion 72:195–200PubMedCrossRefGoogle Scholar
  75. 75.
    Ardizzone S, Puttini PS, Cassinotti A, Porro GB (2008) Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40(Suppl 2):S253–259PubMedCrossRefGoogle Scholar
  76. 76.
    Darvay A (1996) Sweet’s syndrome preceding inflammatory bowel disease. Clin Exp Dermatol 21:175PubMedCrossRefGoogle Scholar
  77. 77.
    Travis S, Innes N, Davies MG, Daneshmend T, Hughes S (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 9:715–720PubMedCrossRefGoogle Scholar
  78. 78.
    Greenstein AJ, Janowitz HD, Sachar DB (1976) The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55:401–412CrossRefGoogle Scholar
  79. 79.
    Cohen PR, Talpaz M, Kurzrock R (1988) Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol 6:1887–1897PubMedGoogle Scholar
  80. 80.
    Ali M, Duerksen DR (2008) Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can J Gastroenterol 22:296–298PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Angelo V. Marzano
    • 1
  • Rim S. Ishak
    • 1
  • Simone Saibeni
    • 2
  • Carlo Crosti
    • 1
  • Pier Luigi Meroni
    • 3
  • Massimo Cugno
    • 4
  1. 1.Unità Operativa di Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore PoliclinicoUniversità degli Studi di MilanoMilanItaly
  2. 2.Unità Operativa di Medicina Interna ed EpatologiaAzienda Ospedaliera Fatebenefratelli e OftalmicoMilanItaly
  3. 3.Division of Rheumatology, Istituto G Pini, Istituto Auxologico Italiano, Department of Clinical Sciences and Community HealthUniversity of MilanMilanItaly
  4. 4.Sezione di Medicina Interna, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore PoliclinicoUniversità degli Studi di MilanoMilanItaly

Personalised recommendations